title: Cytotoxic effects of kainate ligands on HEK cell lines expressing recombinant kainate receptors.
abstract: Exposure of neurons either for prolonged periods of time or to high concentrations of excitatory amino acids (EAA), such as glutamate, results in neuronal death. Kainate also causes cell toxicity through the glutamate receptors. However, it is unclear whether the kainate receptor itself mediates any of the toxic responses. In the present study, HEK cells expressing the GluR6 +/- KA2 receptor subunit(s) were studied for their susceptibility to toxicity through the kainate receptor by kainate ligands. The natural ligand, glutamate, did not result in toxicity to the recombinant cell lines over that observed with the untransfected HEK cells, whereas kainate produced a 2-3-fold increase in LDH in both the HEK/GluR6 (ANOVA, P = 0.0001) and HEK/GluR6 + KA2 (ANOVA, P = 0.0002) cell lines following treatment with various dosages, but did not affect the HEK cells. Similar 2-3-fold increases in LDH activity were detected in both recombinant cell lines following treatment with 100 nM of SYM2081 ((2S,4R)-4-methylglutamic acid), a dose at which agonistic activity is elicited. The rank order potencies for eliciting toxicity are consistent with the previously reported EC50 values (SYM2081 > kainate > > > glutamate). Surprisingly, the kainate antagonist, NBQX, was the most toxic of the compounds tested although it had an affinity for the kainate receptor similar to glutamate. Treatment with as little as 10 nM elicited a dramatic increase in toxicity (6-10-fold) in the recombinant cell lines. At 1 microM, NBQX was significantly more toxic (Fisher PLSD, P < 0.05) than any of the other compounds tested. Thus, it appears that cell toxicity can be mediated via kainate receptor through two independent mechanisms: activation and blockage of the kainate receptor.
authors.affiliation: Symphony Pharmaceuticals, Inc., Department of Molecular Biology, Malvern, PA 19355, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Carver
authors.forename: P E
authors.initials: PE
authors.lastname: Mansson
authors.forename: L
authors.initials: L
authors.lastname: Cortes-Burgos
authors.forename: J
authors.initials: J
authors.lastname: Shu
authors.forename: L M
authors.initials: LM
authors.lastname: Zhou
authors.forename: J R
authors.initials: JR
authors.lastname: Howe
authors.forename: T
authors.initials: T
authors.lastname: Giordano
mesh_terms: D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity*; D018691:Excitatory Amino Acid Antagonists / Q000633:toxicity; D005971:Glutamates / Q000494:pharmacology; D018698:Glutamic Acid / Q000633:toxicity; D006801:Humans; D007608:Kainic Acid / Q000031:analogs & derivatives* / Q000633:toxicity*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008024:Ligands; D011810:Quinoxalines / Q000633:toxicity; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D018092:Kainic Acid Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000096:biosynthesis
chemical_list: D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates; D018698:Glutamic Acid; D007608:Kainic Acid; D007770:L-Lactate Dehydrogenase; D008024:Ligands; D011810:Quinoxalines; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; D011994:Recombinant Proteins; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C046105:4-methylglutamic acid